Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has Aclaris Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ACRS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 64% a week.
Volatility Over Time: ACRS's weekly volatility has increased from 33% to 64% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ACRS exceeded the US Pharmaceuticals industry which returned 11.9% over the past year.
Return vs Market: ACRS exceeded the US Market which returned 56.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Aclaris Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Path To Profitability
3 months ago | Simply Wall StHow Much Of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Do Insiders Own?
4 months ago | Simply Wall StIs Aclaris Therapeutics (NASDAQ:ACRS) Weighed On By Its Debt Load?
Is Aclaris Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ACRS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ACRS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ACRS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ACRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACRS is overvalued based on its PB Ratio (34.7x) compared to the US Pharmaceuticals industry average (3.9x).
How is Aclaris Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACRS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACRS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACRS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACRS's revenue (35.4% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: ACRS's revenue (35.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ACRS's Return on Equity is forecast to be high in 3 years time
How has Aclaris Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACRS is currently unprofitable.
Growing Profit Margin: ACRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACRS is unprofitable, and losses have increased over the past 5 years at a rate of 17.3% per year.
Accelerating Growth: Unable to compare ACRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACRS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).
Return on Equity
High ROE: ACRS has a negative Return on Equity (-135.87%), as it is currently unprofitable.
How is Aclaris Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ACRS's short term assets ($57.5M) exceed its short term liabilities ($14.9M).
Long Term Liabilities: ACRS's short term assets ($57.5M) exceed its long term liabilities ($18.3M).
Debt to Equity History and Analysis
Debt Level: ACRS's debt to equity ratio (28.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ACRS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACRS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ACRS has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 24.9% each year.
What is Aclaris Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Neal Walker (50 yo)
Dr. Neal S. Walker, D.O., Co-founded Aclaris Therapeutics, Inc. in 2012 and also has been its Chief Executive Officer and President since July 2012. Dr. Walker is also Co-Founding Member and Partner of NeX...
CEO Compensation Analysis
Compensation vs Market: Neal's total compensation ($USD3.15M) is about average for companies of similar size in the US market ($USD3.67M).
Compensation vs Earnings: Neal's compensation has been consistent with company performance over the past year.
Experienced Management: ACRS's management team is considered experienced (4.9 years average tenure).
Experienced Board: ACRS's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.9%.
Aclaris Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aclaris Therapeutics, Inc.
- Ticker: ACRS
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.500b
- Shares outstanding: 51.80m
- Website: https://www.aclaristx.com
Number of Employees
- Aclaris Therapeutics, Inc.
- 640 Lee Road
- Suite 200
- United States
Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Th...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 23:00|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.